Etofenamate, formerly known as TVX485 and WHR-5020, is a non-steroidal anti-inflammatory drug used for the treatment of joint and muscular pain. The Etofenamate gel ( 5.0% (w/w) ) with 30% ethanol showed in vivo anti-inflammatory activity with suitable physical chemical and microbiologic characteristics. In vitro release and permeation studies revealed that the different amounts of ethanol used influenced the release profiles of etofenamate. Moreover, it was demonstrated that this formulation is an adequate vehicle for the etofenamate skin permeation.
Physicochemical Properties
| Molecular Formula | C18H18F3NO4 |
| Molecular Weight | 369.3402 |
| Exact Mass | 369.118 |
| CAS # | 30544-47-9 |
| Related CAS # | Etofenamate-d4;1329837-73-1 |
| PubChem CID | 35375 |
| Appearance | Light yellow to yellow ointment |
| Density | 1.3±0.1 g/cm3 |
| Boiling Point | 451.1±45.0 °C at 760 mmHg |
| Melting Point | 25°C |
| Flash Point | 226.6±28.7 °C |
| Vapour Pressure | 0.0±1.2 mmHg at 25°C |
| Index of Refraction | 1.552 |
| LogP | 4.14 |
| Hydrogen Bond Donor Count | 2 |
| Hydrogen Bond Acceptor Count | 8 |
| Rotatable Bond Count | 9 |
| Heavy Atom Count | 26 |
| Complexity | 433 |
| Defined Atom Stereocenter Count | 0 |
| SMILES | O=C(OCCOCCO)C1=CC=CC=C1NC2=CC=CC(C(F)(F)F)=C2 |
| InChi Key | XILVEPYQJIOVNB-UHFFFAOYSA-N |
| InChi Code | InChI=1S/C18H18F3NO4/c19-18(20,21)13-4-3-5-14(12-13)22-16-7-2-1-6-15(16)17(24)26-11-10-25-9-8-23/h1-7,12,22-23H,8-11H2 |
| Chemical Name | 2-(2-hydroxyethoxy)ethyl 2-((3-(trifluoromethyl)phenyl)amino)benzoate |
| Synonyms | TVX485 TVX-485 TVX 485 WHR-5020 WHR 5020 WHR5020 Etofenamate Bay d 1107 Bayrogel Rheumon. |
| HS Tariff Code | 2934.99.9001 |
| Storage |
Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition | Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs) |
Biological Activity
| References | Peraman R, Bhadraya K, Reddy YP, Reddy CS, Lokesh T. Analytical Quality by Design Approach in RP-HPLC Method Development for the Assay of Etofenamate in Dosage Forms. Indian J Pharm Sci. 2015 Nov-Dec;77(6):751-7. PubMed PMID: 26997704; PubMed Central PMCID: PMC4778236. |
| Additional Infomation |
2-[3-(trifluoromethyl)anilino]benzoic acid 2-(2-hydroxyethoxy)ethyl ester is a benzoate ester. Etofenamate is used to treat muscle and joint paint. It is a non-steroidal anti-inflammatory drug (NSAID). |
Solubility Data
| Solubility (In Vitro) |
Ethanol : ~120 mg/mL (~324.90 mM) DMSO : ≥ 50 mg/mL (~135.38 mM) |
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (6.77 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (6.77 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 3: ≥ 2.5 mg/mL (6.77 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly.  (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.7075 mL | 13.5377 mL | 27.0753 mL | |
| 5 mM | 0.5415 mL | 2.7075 mL | 5.4151 mL | |
| 10 mM | 0.2708 mL | 1.3538 mL | 2.7075 mL |